<p class="title">Scientists have developed a high-dose cholera vaccine for controlling outbreaks.</p>.<p class="bodytext">The vaccine, named Vaxchora, is a single-dose, live- attenuated oral vaccine. It was approved in 2016 by the US Food and Drug Administration (FDA) for use in adults (18-64 years).</p>.<p class="bodytext">The study, published in the journal Clinical and Vaccine Immunology, included 150 participants.</p>.<p class="bodytext">The researchers assessed the effectiveness (ability to stimulate vibriocidal antibody, an immune response that correlates with protection) of a single high-dose of live cholera vaccine CVD 103-HgR.</p>.<p class="bodytext">"Immunisation with a single-dose cholera vaccine that could rapidly protect people in low-income countries who have not previously been exposed to cholera would be a significant asset in helping control outbreaks and lower mortality rates," said Myron M Levine, from the University of Maryland in the US.</p>.<p class="bodytext">Cholera transmission is endemic in many areas of Africa, Asia and the Caribbean.</p>.<p class="bodytext">In severe cases, patients pass large amounts of diarrhoea that causes rapid dehydration and ultimately death if left untreated.</p>.<p class="bodytext">This year, the World Health Organisation (WHO) estimated that in Yemen alone there have been a million cases of cholera.</p>
<p class="title">Scientists have developed a high-dose cholera vaccine for controlling outbreaks.</p>.<p class="bodytext">The vaccine, named Vaxchora, is a single-dose, live- attenuated oral vaccine. It was approved in 2016 by the US Food and Drug Administration (FDA) for use in adults (18-64 years).</p>.<p class="bodytext">The study, published in the journal Clinical and Vaccine Immunology, included 150 participants.</p>.<p class="bodytext">The researchers assessed the effectiveness (ability to stimulate vibriocidal antibody, an immune response that correlates with protection) of a single high-dose of live cholera vaccine CVD 103-HgR.</p>.<p class="bodytext">"Immunisation with a single-dose cholera vaccine that could rapidly protect people in low-income countries who have not previously been exposed to cholera would be a significant asset in helping control outbreaks and lower mortality rates," said Myron M Levine, from the University of Maryland in the US.</p>.<p class="bodytext">Cholera transmission is endemic in many areas of Africa, Asia and the Caribbean.</p>.<p class="bodytext">In severe cases, patients pass large amounts of diarrhoea that causes rapid dehydration and ultimately death if left untreated.</p>.<p class="bodytext">This year, the World Health Organisation (WHO) estimated that in Yemen alone there have been a million cases of cholera.</p>